drugset / Trial / NCT05792410
A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study aims to evaluate the safety, tolerability, PK and preliminary anti-tumour activity of SHR-A1811 combined with other therapies in patients with HER2 low advanced or metastatic breast cancer.
Timeline
- Start
- 2023-04
- Primary completion
- 2024-02-27
- Completion
- 2025-02-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 100 mg | Intravenous |
| Subject | Dalpiciclib | Small molecule | 25 mg | Oral |
| Subject | Dalpiciclib | Small molecule | 50 mg | Oral |
| Subject | Dalpiciclib | Small molecule | 125 mg | Oral |
| Subject | Dalpiciclib | Small molecule | 150 mg | Oral |
| Subject | Fulvestrant | Small molecule | 0.25 g | Intramuscular |
| Subject | Trastuzumab Rezetecan | Monoclonal antibody | 100 mg | Intravenous |